Angel Physicians Fund

Angel Physicians Fund, founded in 2020 and based in Powell, Ohio, operates as a venture capital firm specializing in seed-stage investments. Comprised of physicians and medical pioneers, the firm is dedicated to supporting companies in the life sciences and healthcare sectors. With a unique focus on bioscience and health-related ventures, Angel Physicians Fund seeks to leverage the expertise of its members to identify and nurture innovative healthcare solutions.

Manish Bhandari

Managing Partner

6 past transactions

Alphyn Biologics

Series A in 2022
Alphyn Biologics is a life science company focused on developing innovative drug therapies for skin diseases, particularly severe and common skin infections. The company's primary target is infections caused by drug-resistant bacteria, specifically methicillin-resistant Staphylococcus aureus (MRSA). Utilizing its proprietary Multi-Target Therapeutic (MTT) platform, Alphyn Biologics creates topical treatments derived from a tropical plant known for its natural antibacterial properties. This approach aims to address shortcomings in existing treatments, such as efficacy, side effects, and patient tolerability, ultimately providing a safe and effective solution for patients suffering from bacterial skin infections.

PanTher Therapeutics

Series A in 2021
PanTher Therapeutics is a biotechnology company developing cancer drug-delivery technologies. Its core platform enables therapeutics to be delivered directly to the tumor site, reducing systemic toxicity and allowing higher drug concentrations at the target while enabling sustained treatment. This approach aims to improve therapeutic efficacy and outcomes for hard-to-treat cancers by maximizing drug exposure at the tumor while limiting exposure to healthy tissue. Headquartered in Cambridge, Massachusetts, PanTher Therapeutics is advancing investigational candidates, including a lead program in pancreatic cancer, to broaden the potential of precision delivery in oncology.

Elucid

Series A in 2021
Elucid is a Boston-based biotechnology and medical technology company dedicated to enhancing cardiovascular diagnostic imaging through machine learning. The company has developed ElucidVivo, the first FDA-cleared software that evaluates plaque vulnerability from a single computed tomography angiography scan, aiding in the assessment of heart attack and stroke risks as well as informing treatment decisions. Elucid's technology enables objective quantification of arterial plaque extent and stability, providing a cost-effective and non-invasive means of capturing essential patient health information. In addition to its proprietary software, Elucid collaborates with pharmaceutical companies, healthcare providers, and research organizations to offer quantitative image analysis services, ultimately aiming to improve patient outcomes in cardiovascular care.

S4 Medical

Series A in 2021
Founded in 2017, S4 Medical specializes in developing medical devices for cardiac procedures. Its flagship product is a device designed to protect the esophagus during catheter ablation treatments for atrial fibrillation.

Moray Medical

Seed Round in 2021
Moray Medical is a company focused on developing innovative robotic delivery systems for structural heart therapies, specifically targeting edge-to-edge valve leaflet repair. The company aims to enhance the quality of life for millions affected by leaky heart valves by providing cardiologists with advanced tools for mitral valve clip therapies. Moray Medical's proprietary microfluidic robotics technology enables the precise and safe delivery of treatments, utilizing a compact, reusable fluid-drive system that features a digital interface for maneuvering flexible delivery catheters with ease, akin to using a computer cursor. This approach allows for cost-effective interventions, making life-saving heart valve therapies more accessible to a broader range of patients in need.

Foldax

Series D in 2020
Founded in 2013, Foldax designs and manufactures synthetic heart valves using life polymer technology. Its products aim to provide artificial blood pumping support for patients with aortic, mitral, or tricuspid valve disease via percutaneous or surgical delivery.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.